UBS lowered the firm’s price target on Ibotta (IBTA) to $30 from $55 and keeps a Neutral rating on the shares. The expectation reset to “no-growth” buys time for a transformation, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IBTA:
- Ibotta downgraded to Equal Weight from Overweight at Wells Fargo
- Ibotta downgraded to Neutral from Buy at Goldman Sachs
- BofA downgrades Ibotta to Underperform after ‘big miss’
- Ibotta downgraded to Underperform from Neutral at BofA
- Ibotta, Inc. Class A: Buy Rating Maintained Amidst CPID Growth Potential and Stable Revenue Outlook